| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/19/2001 | EP0493485B1 Erection-inducing methods and compositions |
| 12/19/2001 | CN1327452A Fibroblast growth factor with hepatocyte proliferation activity |
| 12/19/2001 | CN1327387A Pharmaceutical formulations in hydroxypropylmenthyl cellulose capsules |
| 12/19/2001 | CN1327385A Anti-bacterial medicinal compositions |
| 12/19/2001 | CN1327382A Improved formulation for topical non-invasive application in vivo |
| 12/19/2001 | CN1327381A Aqueus medicinal compositions |
| 12/19/2001 | CN1327379A Method for improving UV radiation stability of photosensitive sunscreen filters |
| 12/19/2001 | CN1326803A Reaction crystallizing method for improving grain size |
| 12/19/2001 | CN1326784A Colon-releasing oral biological preparation |
| 12/19/2001 | CN1326769A Stone cleaning liquid for curing stone disease of urinary system |
| 12/19/2001 | CN1326766A Blood cooling and psoriasis cleaning Chinese patent medicine capsule for curing psoriasis |
| 12/19/2001 | CN1326751A Paste made of Euphorbia lunulata bunge |
| 12/19/2001 | CN1326749A Insomnic plaster |
| 12/19/2001 | CN1326739A Minocycline vaginal gel |
| 12/19/2001 | CN1326738A Minocycline vaginal effervescent tablets |
| 12/19/2001 | CN1326733A Colon-releasing oral preparation and its preparing method |
| 12/19/2001 | CN1326732A Soft capsule containing vinyl ester and poly ether polymer, its use and producing method |
| 12/19/2001 | CN1326731A Nicardipine hydro-chloride powder injection and its preparing method |
| 12/19/2001 | CN1326730A 气雾剂 Aerosol |
| 12/19/2001 | CN1326729A Medicinal box for curing skin diseases |
| 12/19/2001 | CN1076205C Particles for NMR imaging and method of manufacture |
| 12/19/2001 | CN1076202C Prescription of tonglufutanwan as medicine for activating collaterals and rehabilitating paralysis |
| 12/19/2001 | CN1076200C Medicine for curing cardiovascular diseases |
| 12/19/2001 | CN1076194C Pharmaceutical preparation |
| 12/19/2001 | CN1076193C Chinese medicinal eyedrops |
| 12/18/2001 | US6331540 Enhancing stability of aqueous pharmaceutical composition containing xanthan gum and fluoroquinolone antibiotic drug by adding water-soluble calcium salt |
| 12/18/2001 | US6331539 Sulfonamide and sulfamide substituted imidazoquinolines |
| 12/18/2001 | US6331524 Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy |
| 12/18/2001 | US6331520 Luteinizing hormone releasing hormone peptide agonist or antagonist; or growth hormone releasing factor peptide; nicontinamide aqueous solution |
| 12/18/2001 | US6331318 Carbon-substituted diketopiperazine delivery systems |
| 12/18/2001 | US6331317 Pumping active agent and polymer through static mixer forming an emulsion, flowing through a manifold into quench liquid forming microparticles |
| 12/18/2001 | US6331316 2',3'-dideoxyinosine and methacrylic acid copolymer core; resistance to disintegration; drug release properties |
| 12/18/2001 | US6331315 Powder compositions of unilamellar liposomes |
| 12/18/2001 | US6331314 Amphiphilic substances is pumped to a high-pressure homogenizer with nozzle of hard ceramic plate, liposome dispersion |
| 12/18/2001 | US6331313 Controlled-release biocompatible ocular drug delivery implant devices and methods |
| 12/18/2001 | US6331312 Preparing a calcium deficient apatitic calcium phosphate, implantable bioceramics, synthetic bone graft material, |
| 12/18/2001 | US6331311 Injectable depot gel composition and method of preparing the composition |
| 12/18/2001 | US6331310 Solid dose delivery vehicle and methods of making same |
| 12/18/2001 | US6331309 Hydrogel compositions for the controlled release administration of growth factors |
| 12/18/2001 | US6331298 Wound healing and treatment of fibrotic disorders |
| 12/18/2001 | US6331294 Use of copolymers of monoethylenically unsaturated carboxylic acids as solubilizers |
| 12/18/2001 | US6331205 Aqueous viscous compositions, whether clear or not, for making soft or hard capsules, and method for making films for such capsules |
| 12/18/2001 | CA2156901C Lipid-polymer conjugates and liposomes |
| 12/18/2001 | CA2143070C Oral controlled release liquid suspension pharmaceutical formulation |
| 12/18/2001 | CA2074215C Improved oral dosing formulations of dideoxy purine nucleosides |
| 12/18/2001 | CA2043450C Gels in the form of highly hydrated self-supporting film, the process for their preparation, and their use in therapy of cutaneous lesions and/or pathologies |
| 12/13/2001 | WO2001094645A1 Two-hybrid assay that detects hiv-1 reverse transcriptase dimerization |
| 12/13/2001 | WO2001094547A2 Molecular delivery vehicle for delivery of selected compounds to targets |
| 12/13/2001 | WO2001094001A2 Novel microcapsules |
| 12/13/2001 | WO2001093932A1 Lockout mechanism for aerosol drug delivery devices |
| 12/13/2001 | WO2001093911A2 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | WO2001093890A2 Botulinum toxin implant |
| 12/13/2001 | WO2001093881A1 Immunological substance containing enteroabsorbable anti-inflammatory factor and application thereof |
| 12/13/2001 | WO2001093879A1 Biologically active agents and drugs |
| 12/13/2001 | WO2001093868A1 Buprenorphine-containing patch |
| 12/13/2001 | WO2001093860A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same |
| 12/13/2001 | WO2001093856A1 Medical composition kit for treating lesioned abnormal tissue |
| 12/13/2001 | WO2001093853A1 Management of snoring by oral administration of dimethyl sulfone |
| 12/13/2001 | WO2001093850A2 Methods and compositions using sulodexide for the treatment of diabetic nephropathy |
| 12/13/2001 | WO2001093847A2 Compositions, kits, and methods for promoting defined health benefits |
| 12/13/2001 | WO2001093846A2 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans |
| 12/13/2001 | WO2001093839A1 Member for application of ointment and ointment patch employing the same |
| 12/13/2001 | WO2001093837A2 Protein powder for pulmonary delivery |
| 12/13/2001 | WO2001093836A2 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | WO2001093835A1 Delivery systems for bioactive agents |
| 12/13/2001 | WO2001093834A1 Pharmaceutical composition in liquid form for oral administration of an active principle, with unpleasant, in particular bitter, taste |
| 12/13/2001 | WO2001093833A2 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 12/13/2001 | WO2001093832A2 Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery |
| 12/13/2001 | WO2001093831A2 Low carbohydrate compositions, kits thereof, and methods of use |
| 12/13/2001 | WO2001093830A1 Method for obtaining aqueous formulations of oxidation-sensitive active principles |
| 12/13/2001 | WO2001093829A2 Powder compositions |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001093827A2 Neurotoxin implant |
| 12/13/2001 | WO2001093826A1 Biocompatible synthetic polymer preparations |
| 12/13/2001 | WO2001093807A2 Transdermal delivery |
| 12/13/2001 | WO2001093701A2 Aqueous chondroprotective compositions having defined ph limitations for efficacious delivery |
| 12/13/2001 | WO2001070225A3 Oxazolidinone tablet formulation |
| 12/13/2001 | WO2001068140A3 Opioid formulations |
| 12/13/2001 | WO2001063368A3 Compliance tracking method |
| 12/13/2001 | WO2001052848A3 Functional coating of linezolid microcapsules for oral administration |
| 12/13/2001 | WO2001049276A3 Anhydrous gel comprising nsaid for topical administration to the oral cavity |
| 12/13/2001 | WO2001045668A3 Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| 12/13/2001 | WO2001045642A3 Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease |
| 12/13/2001 | WO2001043696A3 Implant device for implanting cell culture |
| 12/13/2001 | WO2001042424A3 Sphingolipid-containing cationic liposomes for topical delivery of bioactive material |
| 12/13/2001 | WO2001041735A3 Thermosensitive biodegradable hydrogels based on low molecular weight pluronics |
| 12/13/2001 | WO2001041550A3 Topical anesthetic formulation |
| 12/13/2001 | WO2001040243A3 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
| 12/13/2001 | WO2001039800A3 Controlled delivery of antigens |
| 12/13/2001 | WO2001039742A3 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 12/13/2001 | WO2001039741A3 Mitomycin c solution |
| 12/13/2001 | WO2001037820A3 Ionizable indolinone derivatives and their use as ptk ligands |
| 12/13/2001 | WO2001035929A3 Biodegradable polymer composition |
| 12/13/2001 | WO2001032852A3 Method for directed packaging of molecular substances in protein shells |
| 12/13/2001 | WO2001032139A3 Method for the formulation of substances having a low water-solubility and lipophilicity and formulation thus obtained |
| 12/13/2001 | WO2001026637A3 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
| 12/13/2001 | WO2001021008A3 Method for increasing pet activity |
| 12/13/2001 | WO2001019362A3 Formulations for treating or preventing mucositis |
| 12/13/2001 | WO2000032179A3 Use of nicotonic acid derivatives for the treatment of dna damage in skin cells |
| 12/13/2001 | WO2000032167A9 A polysome |